<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332397</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02206</org_study_id>
    <nct_id>NCT00332397</nct_id>
  </id_info>
  <brief_title>The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis</brief_title>
  <acronym>ISAR-TEST-2</acronym>
  <official_title>Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of 3 different drug-eluting-stent
      platforms to reduce coronary artery reblockage after stent implantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery reblockage remains still a drawback of percutaneous coronary interventions
      even in the era of drug-eluting stents (DES). DESs working principle consists of the delivery
      of controlled amounts of antiproliferative agents at the local level, which results in the
      suppression of neontimal proliferation, the main cause of lumen re-narrowing after stent
      implantation.At present, several DES platforms have been developed and evaluated for clinical
      use. They differ between them with regard to the stent type, anti-proliferative drug,
      presence of polymers employed for drug storage and modification of drug-release kinetics as
      well as type of polymer used for this purpose. Most of the DES platforms have used agents
      from the &quot;limus family&quot;. Although the majority of DESs employ polymer coating to control drug
      storage and release, in view of the increasing safety and efficacy associated with the
      long-term presence of polymers a strong interest has recently been shown in the development
      DES platforms that do not require permanent polymers. Trials as ACTION or JUPITER II have
      demonstrated that not all DESs are associated with the expected improved outcomes. On the
      other hand, not all successful DESs have been equally effective in the reduction of
      restenosis. Thus, rapamycin-eluting stents (Cypher stents) have been associated with lower
      angiographic and clinical restenosis rates than paclitaxel-eluting stents (Taxus stents).
      Similarly, Cypher stents have been superior to Endeavor stents regarding the primary end
      point of late luminal loss in the recent ENDEAVOR III trial. Meanwhile, the on-site
      rapamycin-coated stents (ISAR stents) had an equivalent antiproliferative efficacy to Taxus
      stents in the ISAR-TEST trial. However, none of these studies evaluated angiographic
      restenosis as their primary endpoint and no direct comparisons between the 3 DES -Cypher,
      Endeavor and ISAR stents, have been performed. The Cypher stent is a stainless steel stent
      coated with sirolimus with use of permanent polymers while the Endeavor stent is a cobalt
      alloy based stent coated with zotarolimus which also uses permanent polymers for drug-storage
      and release. The ISAR stent is a rough surface stainless steel stent that can be coated with
      sirolimus in the cath lab without requiring permanent polymeric coating.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the study is the incidence of binary angiographic restenosis at 6-8 month follow-up angiography, measured by QCA in the in-segment area.</measure>
    <time_frame>6-8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The need of target lesion revascularization defined as any revascularization procedure involving the target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia.</measure>
    <time_frame>9-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combined incidence of death or myocardial infarction.</measure>
    <time_frame>9-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent late luminal loss.</measure>
    <time_frame>9-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent thrombosis.</measure>
    <time_frame>9-12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1007</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapamycin-eluting Stent (Cypher)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zotarolimus-eluting Stent (Endeavor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapamycin-eluting Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin-eluting Stent</intervention_name>
    <description>due to randomization, Cypher stent will be implanted</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-eluting Stent</intervention_name>
    <description>due to randomization, Endeavor stent will be implanted</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Endeavor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin-eluting Stent</intervention_name>
    <description>due to randomization, rapamycin-eluting stent will be implanted</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients older than age 18 ´ presence of ischemic symptoms or evidence of myocardial
        ischemia in the presence of ≥50% de novo stenosis located in native coronary vessels
        written, informed consent by the patient or her/his legally-authorized representative for
        participation in the study.

        Exclusion Criteria:

        Target lesion located in the left main trunk or bypass graft In-stent restenosis
        Cardiogenic shock Malignancies or other comorbid conditions with life expectancy less than
        one year or that may result in protocol non-compliance Known allergy to the study
        medications: aspirin, clopidogrel, zotarolimus, sirolimus, stainless steel, or cobalt alloy
        Pregnancy (present, suspected or planned) or positive pregnancy test Previous enrollment in
        this trial Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schoemig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schömig A; Intracoronary Stenting and Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006 Jan 17;113(2):273-9. Epub 2006 Jan 3.</citation>
    <PMID>16391155</PMID>
  </reference>
  <reference>
    <citation>Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005 Aug 18;353(7):663-70. Epub 2005 Aug 16.</citation>
    <PMID>16105990</PMID>
  </reference>
  <reference>
    <citation>Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schömig A; investigators of the individualizable durg-eluting Stent System to Abrogate Restenosis Project. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005 Aug;26(15):1475-81. Epub 2005 Jun 23.</citation>
    <PMID>15975990</PMID>
  </reference>
  <reference>
    <citation>Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005 Aug 18;353(7):653-62. Epub 2005 Aug 16.</citation>
    <PMID>16105989</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schömig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L, Virmani R; ACTION investigators. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol. 2004 Oct 6;44(7):1363-7.</citation>
    <PMID>15464314</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Dibra A, Eberle S, Mehilli J, Suárez de Lezo J, Goy JJ, Ulm K, Schömig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005 Aug 17;294(7):819-25.</citation>
    <PMID>16106007</PMID>
  </reference>
  <reference>
    <citation>Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80.</citation>
    <PMID>12050336</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2006</study_first_submitted>
  <study_first_submitted_qc>May 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2006</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

